Day: June 21, 2022

TORONTO, June 21, 2022 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase®’s Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has been peer reviewed and published in the European Urology Open Science (“EUOS”) Journal , Volume 41, July 2022. According to EUOS’s website, EUOS is dedicated to the publication of high quality, innovative research that will benefit patients with urological conditions. EUOS covers research in the urological field, including clinical, basic and translational...

Else’s expansion into the retailer’s 133 stores in the summer of 2022 expects to boost its national presence and reach millions of new shoppers VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) announces that its Plant-Based complete Nutrition products for babies, toddlers, and kids will soon be available at over 130 locations of buybuy BABY – the leading specialty retailer of baby products in North America. “The expansion into buybuy BABY marks another major milestone for the Company,” said Hamutal Yitzhak, CEO, and Co-Founder of Else Nutrition. “This makes our Complete, Clean Label, Plant-Based Nutrition products for early childhood accessible to millions more wanting shoppers, in North America’s...

Image 1 Mr. Saxon, who is now Chief Executive Officer of TAAT®, served in various positions for over 20 years with Altria and PMI including heading Altria’s Corporate Venture Fund and leading PMI’s business activities as General Manager for Norway and Denmark. He has led business units with full profit and loss (P&L) responsibility ranging from USD $100 million to USD $3 billion while consistently delivering record business resultsMichael Saxon, who has been appointed Chief Executive Officer of TAAT®, served in various positions for over 20 years with Altria and PMI including heading Altria’s Corporate Venture Fund and leading PMI’s business activities as General Manager for Norway and Denmark. He has led business units with full profit and loss (P&L) responsibility ranging from USD $100 million to USD $3 billion while consistently...

TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos’ innovation pipeline and commercialization strategy. Launched in 2018 with the goal of accessing rare molecules in the cannabis plant to create innovative...

BRIDGEVILLE, Pa., June 21, 2022 (GLOBE NEWSWIRE) — Universal Stainless & Alloy Products, Inc. today reported that operations at its Bridgeville Electric Arc Melting facility resumed in May as anticipated and have now returned to full operating capacity following a metal spill that occurred in April. The spill was caused by a breakthrough at the bottom of a furnace shell. No one was injured and there was no environmental impact. All other operations continued to function normally and there were no near term interruptions to product delivery schedules. Chairman, President and CEO, Dennis Oates commented: “I am very pleased to report that our Melt Shop is back up and running. Our team accomplished this on schedule, even as they dealt with substantial clean-up and other challenges. Business conditions remain strong and our backlog...

MONTREAL, June 21, 2022 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (“Brunswick” or the “Corporation”) (TSX-V: BRW) is pleased to announce that on April 26, 2022, its Board of Directors of Brunswick approved an amendment to the stock option plan of Brunswick (the “Stock Option Plan”) to increase the number of common shares of the Corporation reserved for issuance under the Stock Option Plan from 5,000,000 to 13,000,000. The Corporation has also received approval from the TSX Venture Exchange on the extension of 3,071,199 common share purchase warrants (the “Warrants”) which were issued as part of the private placement of the Corporation on May 17, 2022. The Warrants, originally set to expire on May 17, 2024, will now expire on May 17, 2025. Holders of Warrants will not receive an amended Warrant certificate. A portion of the...

XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial Plans to initiate XEN1101 Phase 3 clinical trial (X-ACKT) in an additional epilepsy indication of primary generalized tonic clonic seizures BURNABY, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced next steps in its clinical program evaluating XEN1101 for the treatment of patients with focal onset seizures (FOS) following the completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food & Drug Administration (FDA). The outcome of the EOP2 meeting...

GameOn Appoints David Meltzer to Board of Directors GameOn Appoints David Meltzer to Board of DirectorsMeltzer is the Co-Founder of Sports 1 Marketing and the former CEO of Leigh Steinberg Sports & Entertainment, the inspiration for the Jerry Maguire movie, as well as a best-selling author, Top 100 Business Coach, and Apple TV and Netflix Executive ProducerVANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) —  GameOn Entertainment Technologies Inc. (“GameOn” or the “Company”) (CSE: GET) (OTCQB: GMETF), a leading web3 game technology company partnered with the world’s biggest IPs to launch, operate, and monetize web3-based prediction and fantasy games, announces the appointment of David Meltzer to the Board of Directors, effective June 16, 2022. Meltzer is the Co-Founder of Sports 1 Marketing and formerly served...

ATLANTA, June 21, 2022 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled warehouses and logistics for the food industry, today announced the grand opening of its newest facility in Dunkirk, NY. With 181,000 square feet of cold storage and operational space, this LEED-certified facility features 25,000 pallet positions, to support cold storage needs in the western New York region. “This is our first facility in western New York, and we’re excited to expand in this area at the request of our customers,” said George Chappelle, Chief Executive Officer at Americold. “Our goal is to provide the best-in-class service to all of our customers and this facility will help us to do that in New York.” The new facility, which is holding grand opening ceremonies today, is located on Williams Street,...

WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKSE: 1477), a fast-growing ophthalmology focused pharmaceutical company in China, today announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is the first drug approved for commercialization in China based entirely on real-world data, as well as the first drug approved for commercial use in OcuMension’s innovative pipeline. In...